Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (681)	5/19/2005 8:07:38 AM
From: gcrispin	Read Replies (2) \| Respond to of 946

<One doubt raised by a questioner was whether or not all the Eastern Europe patients even had lung cancer. He just couldn't believe the survival stats. And, EE had more in the control arm than the ROW.> What some might not realize is that Dr. Edward Gabrielson, the person who raised this question, in not an analyst, but a molecular pathologist who is a member of the faculty at John Hopkins. His specialty is in lung and breast cancer. His suggestion that they review the pathology reports on the ROW patients was met by silence. It was the first time I ever heard Bianco unable to respond in a Q&A.